Clinical trial · Observational
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer
Comparative Study of Tumor Microenvironment Between Early and Advanced Prostate Cancer Through Multi-omics
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In recent years, the clinical research of immunotherapy including PD-1 antibody and CD3 bispecific antibody in prostate cancer has been increasing day by day. The comparison with the analysis results of cancer tissues of advanced patients has important guiding significance for the application of these new treatment methods. In a retrospective study, investigators plan to perform multi-omics analysis (including whole exome, RNAseq), immune cell characterization, and biopsy samples from prostate cancer primary biopsy, ADT neoadjuvant, and CRPC biopsy samples in the biobank. Protein and prostate cancer-specific antigen expression were analyzed by immunohistochemistry. The following questions are answered by comparing samples from different treatment stages in early and advanced stages: 1. Whether the immune environment becomes "cold" in the advanced stage; 2. Which immune cell populations have changed significantly; 3. Is the inhibitory immune microenvironment related to genes Mutations or suppressive immune cell populations.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Neoadjuvant
- description
- From the beginning of the project for the past five years to the next three years, underwent prostate cancer biopsies at the First Affiliated Hospital of Xi'an Jiaotong University before neoadjuvant therapy, and underwent radical prostatectomy after 3-6 months of neoadjuvant therapy.
- label
- CRPC
- description
- Patients with CRPC-diagnosed prostate cancer after initial continuous ADT therapy, with serum testosterone reaching castration levels (\<50ng/dl or \<1.7nmol/L) but with progressive disease, and who were diagnosed with CRPC at Xi'an Jiaotong University The First Affiliated Hospital did a prostate cancer biopsy.
Primary outcomes (3)
- measure
- FFPE samples requirements
- timeFrame
- From the date of participants recruitment to the date of collection of at least 80 eligible FFPE samples, assessed up to 36 months.
- description
- 1. H\&E stained slide (tumor area marked, tumor content \>= 20%). 2. Standard sample request:5-10 unstained slides, thickness 4-5um,0.6mm3 (matched to H\&E slide).
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * The patient was diagnosed with prostate cancer. * The patient underwent neoadjuvant therapy or was diagnosed with CRPC. Exclusion Criteria: * When it is detected that the patient has a viral infection that interferes with the human genome, such as HIV infection, etc. * Biopsy and/or surgically removed prostate cancer tissue was not eligible for the study.
References
Publications (0)
Data not yet available